In a study based on NK cell isolation from patients with MDS, authors showed that CD33 × CD16 BiKE potently activates blood and marrow MDS–NK cells at all disease stages to lyse CD33+ MDS and CD33+ myeloid-derived suppressor cells (MDSCs) targets (159). The gene discussed is CD33; the disease is myelodysplastic syndrome.